Payment overview · 2025
General Payments
$162.97
10 reported records · 7 companies
Healthcare provider profile · identity verified
Matthew B Sutton, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OVERLAND PARK, KS · NPI 1598787186
Verified facts
What the public records show
CMS Open Payments records show Matthew B Sutton, M.D. received $162.97 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Arexvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.96 | 21.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.36 | 19.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.72 | 18.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.29 | 13.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.71 | 9.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.42 | 8.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.51 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $162.97 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
126 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
56 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 878 | 266 |
| Amlodipine Besylate | Amlodipine Besylate | 601 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 374 | 115 |
| Lisinopril | Lisinopril | 281 | 79 |
| Omeprazole | Omeprazole | 281 | 88 |
| Losartan Potassium | Losartan Potassium | 234 | 76 |
| Simvastatin | Simvastatin | 214 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 69 |
| Famotidine | Famotidine | 196 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 56 |
| Metformin Hcl Er | Metformin Hcl | 182 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 47 |
| Sertraline Hcl | Sertraline Hcl | 160 | 56 |
| Potassium Chloride | Potassium Chloride | 139 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 48 |
| Carvedilol | Carvedilol | 127 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 44 |
| Synthroid | Levothyroxine Sodium | 126 | 32 |
| Trazodone Hcl | Trazodone Hcl | 125 | 42 |
| Azithromycin | Azithromycin | 124 | 89 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 33 |
| Ezetimibe | Ezetimibe | 97 | 34 |
| Gabapentin | Gabapentin | 97 | 37 |
| Metformin Hcl | Metformin Hcl | 89 | 33 |
| Methylprednisolone | Methylprednisolone | 88 | 66 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | 23 |
| Spironolactone | Spironolactone | 76 | 23 |
| Finasteride | Finasteride | 71 | 24 |
| Ramipril | Ramipril | 66 | 19 |
| Allopurinol | Allopurinol | 65 | 19 |
| Alprazolam | Alprazolam | 62 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 22 |
| Eliquis | Apixaban | 61 | 21 |
| Januvia | Sitagliptin Phosphate | 61 | 16 |
| Irbesartan | Irbesartan | 60 | 19 |
| Montelukast Sodium | Montelukast Sodium | 60 | 16 |
| Furosemide | Furosemide | 59 | 25 |
| Valsartan | Valsartan | 59 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 56 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 20 |
| Glimepiride | Glimepiride | 51 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 16 |
| Amoxicillin | Amoxicillin | 46 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 13 |
| Acyclovir | Acyclovir | 37 | 19 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 13 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Jardiance | Empagliflozin | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 18 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Clonazepam | Clonazepam | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $162.97 · 10 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, FREESTYLE LIBRE 3, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SHINGRIX, UBRELVY, XIFAXAN, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error